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Abstract
Background: Preterm birth contributes to 0.5 million deliveries in the United States (one of eight pregnancies) and
poses a huge burden on public health with costs in the billions. Of particular concern is that the rate of earliest
preterm birth (<34 weeks) (ePTB), which has decreased little since 1990 and has the greatest impact on the overall
infant mortality, resulting in the greatest cost to society. Docosahexaenoic acid (DHA) supplementation provides a
potential high yield, low risk strategy to reduce early preterm delivery in the US by up to 75%. We propose a Phase
III Clinical Trial (randomized to low or high dose DHA, double-blinded) to examine the efficacy and safety of high
dose DHA supplementation to reduce ePTB. We also plan for a secondary pregnancy efficacy analysis to determine
if there is a subset of pregnancies most likely to benefit from DHA supplementation.
Methods: Between 900 and 1200 pregnant women who are ≥ 18 years old and between 12 and 20 weeks gestation
will be recruited from three trial experienced academic medical institutions. Participants will be randomly assigned to
two daily capsules of algal oil (totaling 800 mg DHA) or soybean and corn oil (0 mg DHA). Both groups will receive a
commercially available prenatal supplement containing 200 mg DHA. Therefore, the experimental group will receive
1000 mg DHA/d and the control group 200 mg DHA/d. We will then employ a novel Bayesian response adaptive
randomization design that assigns more subjects to the “winning” group and potentially allows for substantially smaller
sample size while providing a stronger conclusion regarding the most effective group. The study has an overall Type I
error rate of 5% and a power of 90%. Participants are followed throughout pregnancy and delivery for safety and
delivery outcomes.
Discussion: We hypothesize that DHA will decrease the frequency of ePTB <34 weeks. Reducing ePTB is clinically
important as these earliest preterm deliveries carry the highest risk of neonatal morbidity, as well as contribute
significant stress for families and post a large societal burden.
Trial registration: This trial was registered with ClinicalTrials.gov (identifier: NCT02626299) on December 8, 2015.
Additional summary details may be found in Table 1.
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Background
DHA intake and status of US women during pregnancy
and physiological importance
Docosahexaenoic acid (DHA) is a long-chain polyunsatur-
ated fatty acid member of the n-3 (or omega-3) fatty acid
family. DHA is found in animal foods with the richest
sources being varieties of ocean fish [1]. On average, US
women consume ~60 mg DHA/day [2] but synthesize lit-
tle DHA from the α–linolenic acid (18:3n-3) they con-
sume in other foods [3, 4]. DHA intake among US women
is lower than other Western populations [2]. Two com-
monly used indicators of DHA status: 1) red blood cell
phospholipid (RBC-PL) DHA as a percent of total
membrane fatty acids [5, 6] and 2) human milk DHA as a
percent of total fatty acids [7] are lower in US women
than in other developed countries. For example, base-
line RBC-PL-DHA means ranged from 4.3 to 5.0% in
our last three Kansas City pregnant cohorts [5, 8, 9]
compared to greater than 6% RBC-PL-DHA reported
by others [10–12]. The US rate of preterm birth (PTB)
(<37 weeks) is also higher than other developed coun-
tries [13]. The NICHD Maternal Fetal Network multi-
center trial notes the highest rate of PTB for women in
the lowest quartile for RBC-PL-DHA (OR 1.45) [14].
Worldwide, 24% of all PTBs occur in India, where
vegetable-based diets low in DHA are common [13].
US studies typically report a mean of 0.15–0.2% DHA
in human milk [7, 15, 16] in contrast to countries and
groups where ocean fish are routinely consumed (0.5 to
2.7%) [17, 18]. Our pilot feasibility trial found extremely
low milk DHA in women consuming a placebo, but milk
DHA increased to 0.5–0.7% in the group assigned to re-
ceive a dietary supplement of 1000 mg of DHA/day [16]
(Fig. 1). Pregnant women consuming more DHA also
provide more DHA to their fetus and after delivery, have
higher milk DHA during lactation. It is well established
that the biosynthesis of DHA from α-linolenic acid is
very limited [3, 4], especially under several conditions
including caloric deprivation, protein inadequacy, and
corticosteroids, which inhibit the δ6-desaturase and,
therefore, DHA synthesis [19] (Fig. 2). In fact, there have
been many attempts to increase DHA status and milk
DHA by feeding α–linolenic acid without success.
Preformed dietary DHA found in marine life, algal
sources, or eggs can produce immediate biologic effects.
Dietary DHA also increases DHA in membranes of cells
from all organs that have been studied. Higher DHA
status is linked to a number of positive health outcomes in-
cluding protection against cardiovascular disease [20, 21],
breast cancer [22–24], and Alzheimer’s disease [25–28]
and more recently to resolution of inflammation [29–31]
and neuroprotection [32, 33]. Higher DHA status during
development is linked to higher cognitive performance
[34–37], lower allergy [38–41], and lower adiposity [42]. In
summary, DHA is found in some foods but little is synthe-
sized from α-linolenic acid. DHA intake and status of US
women are among the lowest in the world.
Effects of DHA and EPA supplementation on gestation
duration, preterm birth, ePTB and VLBW
DHA status in pregnancy was first linked to longer gesta-
tion, higher birth weight, and less PTB by early studies of
Olsen and collaborators [43, 44] after they observed longer
gestation among the Faroe Islanders who consumed higher
DHA and EPA compared to the Danes [43]. Three recent
systematic reviews address the question of pregnancy out-
comes in randomized trials of total omega-3 long chain
polyunsaturated fatty acid (LCPUFA) supplementation
[45–47]. A 2006 Cochrane review that included six trials
with 2755 women [45] found a 2.6-day increase in gesta-
tion duration favoring supplementation (P = 0.0009). Only
one review found a significant reduction in overall PTB
(<37 weeks) (P values = 0.03–0.29) [45–47], but all re-
ported a reduction in early preterm birth (ePTB) (<34
weeks) with odds ratios favoring supplementation of 0.42
to 0.74. However, the ePTB findings are based on only
three studies that provided DHA in amounts of 800–
2000 mg/d. While two trials conducted in Australia and
Europe found a reduction in ePTB [48, 49], the US trial
conducted by the NICHD Maternal Fetal Network trial ob-
served no decrease in ePTB despite supplementation with
800 mg DHA/d. The absence of an effect in this trial may
be linked to the fact the trial included only women with a
prior preterm birth and all received weekly injections of
progesterone [50]. In contrast, only 4.9% of women in our
Kansas City KUDOS study had a prior PTB and only 2.3%
(n = 7) a prior ePTB (one had a repeat ePTB in our study).
None received progesterone for short cervix. The potential
of DHA to reduce ePTB is plausibly linked to its role in re-
ducing inflammation, a final pathway for spontaneous
Fig. 1 Effect of DHA supplementation on milk DHA content
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ePTB. After the first two systematic reviews were pub-
lished, our US trial was published, reporting significantly
less ePTB (4.8 vs 0.6%, P = 0.025), fewer very low birth
weight (VLBW) births (3.4 vs 0%, P = 0.026) and fewer days
in hospital for infants born preterm (40.8 vs 8.9 day,
P = 0.026) in the group supplemented with 600 mg/d
DHA compared to placebo [5]. We conclude from
studies conducted around the world that a high dose
of DHA supplementation can reduce ePTB. No study
has evaluated high dose DHA supplementation as a
primary outcome to reduce ePTB, which we propose
to do in a US population known to have poor DHA
status before and during pregnancy.
Importance of reducing ePTB and what the evidence
suggests may be happening with high dose DHA
supplementation
Overall ePTB rate in the US for 2012 was 3.4% [51];
however, the ePTB rate for non-Hispanic blacks (7.0%)
was higher than for non-Hispanic whites (3.3%). ePTB
compared to late PTB (≥34 weeks–37 weeks) carries a
much greater risk of infant morbidity and mortality and
costs society billions of dollars. Three systematic re-
views [45–47], one conducted after publication of our
trial [5] find a significant reduction in ePTB with high
dose DHA supplementation. Biomarkers assessed prior
to 20 week gestation suggest that the risk of spontan-
eous preterm labor has an early etiology from stressors
linked to inflammation particularly PTB due to pro-
longed rupture of membranes and chorioamnionitis
[52–55]. We hypothesize that DHA will prolong gesta-
tion duration for a period of time that will be sufficient
for the fetus to require less medical intervention; i.e.,
that DHA will both reduce ePTB and improve neonatal
outcome.
Mechanisms by which DHA might reduce ePTB
DHA unlike other omega-3 fatty acids (α–linolenic acid
and eicosapentaenoic acid (EPA)) uniquely modulates
cell surface ligands to attenuate inflammation, demon-
strated in both humans and animal models [56–60].
While the mechanism of preterm parturition remains
elusive and complex [61], DHA has plausible cellular ef-
fects that could modify the onset or change the timing
of inflammation [62, 63] and promote the activation of
SIRT1 expression directly impacting endothelial relax-
ation [64], or altering membrane fluidity [64, 65] and cell
signaling [66, 67]. It is now recognized that DHA re-
leased from phospholipids in cell membranes serves as a
precursor for docosanoids (22 carbon mediators such as
resolvins, protectins, and maresins) that are anti-
inflammatory, resolve inflammation, and protect against
inflammation [31, 68–72] (Fig. 2). While it is generally
believed that fish oil (a source of both DHA and EPA)
increases gestation duration because EPA competes with
arachidonic acid (ARA), the source of the 2-series pros-
taglandins E2 and F2α required for labor and delivery
[73, 74], we provided only DHA in our previous trial.
Moreover, the effect of DHA supplementation in our trial
and the Australian trial was significant for early births
only; i.e., we find no evidence DHA increases gestation in
general or in any other select group of pregnancies.
A recent pilot study observed a lower preterm, prema-
ture rupture of the membranes (PPROM) in frequent
fish eaters randomly supplemented with only 100 mg
DHA/d [75] further linking DHA intake to reduced in-
flammation. We speculate that pregnancies at risk for
ePTB include a disproportionate number with inflamma-
tion. sRAGE is positively linked to chorioamnionitis and
preterm labor [58] and LPS-induced inflammation in a
murine model [76]. In the latter example, the increase in
sRAGE was attenuated by DHA supplementation.
Fig. 2 Biochemical pathways for DHA synthesis
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sRAGE is negatively associated with IL-6, sepsis and
FIO2 requirements in PT cohorts [53, 58, 77], however,
sRAGE has not been compared in term and preterm
pregnancy. We propose to determine if the higher DHA
supplementation influences either maternal or cord
blood sRAGE as a possible mechanism of DHA PTB
preventive activity.
Rationale for DHA doses
The Institute of Medicine does not set a Dietary Reference
Intake (DRI) for DHA in pregnancy; however, the FAO/
WHO and expert groups suggest an intake of 200 mg of
DHA per day for pregnancy and lactation [78–80]. Many
US prenatal vitamins now contain 200 mg of DHA, and
15% of women in our trial took a DHA supplement. We
propose to compare this low, recommended dose of DHA
(control group) to a high dose of DHA supplement (ex-
perimental group). We chose 1000 mg as a high dose be-
cause doses up to 2000 mg/d of DHA have reduced ePTB
in populations that consume more DHA than in the US
[47–49]. More DHA may be helpful in the US where in-
take and status at baseline are low. Trials providing less
than 600 mg DHA have not found a reduction in ePTB
[81, 82]. DHA is a nutrient and intake and status are
inherently variable. Women with low DHA status may
require more DHA to reach an intake to reduce ePTB. All
nutrients have an intake that is optimal for a given out-
come and the ability to improve that outcome with sup-
plementation is based on an individual’s status at baseline
(Fig. 3). Overall, subjects in our previous trial had a very
low DHA status (mean RBC-PL-DHA= 4.3%) consistent
with DHA deficiency [83]. We identified three clusters in
the DHA supplemented group of KUDOS (Fig. 4). Cluster
1 includes the majority of the DHA group and was exceed-
ingly deficient with a mean baseline RBC-PL-DHA = 3.5%.
Nutritional approach to reduce ePTB and VLBW
There is currently no accepted method for predicting preg-
nancies that will end in spontaneous ePTB and no known
treatment to prevent the occurrence of spontaneous ePTB
with the possible exception of progesterone therapy for
women with cervical lengths of ≤20 mm [84, 85]. In con-
trast, to our US trial, the larger DOMInO trial conducted
in Australia excluded pregnant women with serious mater-
nal illness and found a significant reduction in ePTB with
600 mg/d DHA (n = 301, 0.6% vs. 4.8% of births) and
800 mg/d DHA (n = 2399, 1.1% vs 2.2% of births), respect-
ively. As mentioned above, the presumed effect of DHA is
reduction/resolution of inflammation, a joint mechanism
for both cervical ripening and spontaneous ePTB. Even in
the NICHD trial, women with the lowest DHA blood
concentrations were more likely to have a recurrent
spontaneous PTB [86]. In both our trial and DOMInO, the
incidence of ePTB in the placebo group was similar to the
incidence within the country. These trials and two system-
atic reviews suggest that a high dose supplement of DHA
could effectively reduce ePTB. We feel such an approach
could be particularly useful in pregnant US women whose
DHA status is among the lowest of any population in the
world. It is well known that 500–1000 mg DHA/d in adults
improves clinical biomarkers of inflammation, systemic
























Zone of therapeutic effect
Fig. 3 Role of nutrient status on physiological response
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DHA intake shifts immune homeostasis towards a
more pro-inflammatory response. We propose to com-
pare 1000 mg DHA to 200 mg DHA/d. The lower
amount of DHA is found in many currently available
prenatal supplements, while the studies that have found
an effect of DHA on ePTB have provided between 600
and 900 mg/d [5, 48, 49].
Research objectives
The primary purpose of this multicenter, randomized,
double-blind, controlled Phase III clinical trial is to
determine if DHA supplements totaling 1000 mg/d
compared to 200 mg/d during the last two trimesters
of pregnancy can reduce spontaneous ePTB (<34
weeks gestation) (Specific Aim 1) and to conduct a
secondary pregnancy efficacy analysis to determine if
there is a subset of pregnancies most likely to benefit
from DHA supplementation (Specific Aim 2). To ob-
tain information about the effects of DHA on inflam-
mation, we will measure sRAGE, which is plausibly
influenced by DHA supplementation based on a mur-
ine model of LPS-induced inflammation and bank
plasma samples to determine the impact of DHA on
the transcriptome which broadly reflects a range of
physiologic processes (Specific Aim 3). We will per-
form a prospective randomized comparative effective-
ness adaptive design study with pregnant women to
enhance efficiency of the trial and expedite results to
the research community and to guide clinical practice.
First analysis will be by intent-to-treat. Safety data
will be collected as required for Phase III RCTs
(Specific Aim 4). We will bank umbilical cord blood
at delivery to be available for future evaluations. A
trial summary and registration details can be found in
Table 1.





Date of registration December 8, 2015
Secondary identifying
numbers
R01 HD083292; IND 129482; IRB
STUDY00003455
Source of monetary or
material support
National Institute of Child Health
and Human Development






Contact for public queries Beth Kerling, MS RD (ekerling@kumc.edu)
Contact for scientific
queries
Susan Carlson, PhD (scarlson@kumc.edu)
Public title Assessment of DHA On Reducing Early
preterm Birth (ADORE) Trial
Scientific title Docosahexaenoic Acid Supplementation
in Pregnancy to Reduce Early Preterm Birth




Interventions Active treatment: 1,000 mg DHA per day
Standard of care: 200 mg DHA per day
Key inclusion and exclusion
criteria
Ages eligible for study: ≥ 18 years
Genders eligible for study: female
Accepts healthy volunteers: yes
Inclusion criteria: pregnant female ≥ 18
years; 12–20 weeks of gestation, agree to
consume study capsules; available by
telephone
Exclusion criteria: multiple gestation,
unwilling to discontinue use of another
prenatal supplement with DHA, allergy
to any component of DHA product









Date of first enrollment June 8, 2016
Recruitment status Active recruitment
Primary outcome Occurrence of early preterm birth
Key secondary outcomes Efficacy analysis for subset populations
Effect of DHA on inflammation
Safety evaluation
Fig. 4 Clusters in DHA status at enrollment and birth from an earlier
trial of DHA supplementation during pregnancy
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Methods/Design
The Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) guidelines [87] are followed
for design and conduct of this trial.
Participants and eligibility criteria
Women who are 18 years and older and are in their 12th
to 20th week of gestation based on ACOG guidelines
[88] will be eligible for enrollment. Pregnant women
who receive prenatal care in obstetrics clinics of all 3
participating centers (University of Kansas Medical
Center University of Cincinnati, and The Ohio State
University) receive an ultrasound assessment at ap-
proximately 12 weeks gestation. The estimated date of
delivery (EDD) determined by ACOG guidelines at this
assessment will be fixed as the EDD for assessment of
gestation duration in the study. Women must be able to
read or orally understand the study in English or
Spanish. They must agree at enrollment to consume the
capsules assigned to them from enrollment through
delivery.
Women with a multiple gestation will be excluded, as
the background rate of PTB and low birthweight are
higher likely for reasons other than hypothesized with
DHA. The availability of a telephone is necessary for
optimal coordination of both phases of the study. We
routinely obtain additional phone numbers of friends
and family who have a stable address. The complete
inclusion and exclusion criteria are illustrated in Table 2.
Recruitment and enrollment
Potential participants will be approached by trial re-
cruiters in the ambulatory units of each study site if a
preliminary evaluation suggests they meet the inclusion
and exclusion criteria. The goal is approximately equal
enrollment at the 3 centers with up to 400 subjects en-
rolled per center (depending upon the dictates of the
Bayesian response adaptive randomization). We expect
to enroll 2–3 subjects per week at each of the three
centers (6–9 subjects/week total) and anticipate 11% will
be lost over the course of the study.
Subjects who consent will be asked to provide blood on
the day they are enrolled for fatty acid analysis of RBC-PL
fatty acids, sRAGE and to bank plasma, serum and white
cells for future nutrient and marker analysis. A urine sam-
ple will be collected for measurement of endocrine disrupt-
ing chemicals. Participants will complete the National
Cancer Institute Diet History Questionnaire (NCI DHQ-II)
to obtain information regarding maternal dietary intake,
and additional questions will be asked regarding nutritional
supplement intake prior to and during pregnancy. Medical
and social histories will also be obtained and tracked
throughout pregnancy and delivery. A complete schedule
of participant events is illustrated in Table 3.
Randomization and implementation
A maximum number of pregnant women nmax = 1200
(we plan for 1355 enrollments due to expected dropout)
will be randomized to one of two arms, either algal oil
as a source of DHA (800 mg DHA in two capsules) or
placebo oil (two capsules of half soybean oil and half
corn oil, without DHA). In addition, all participants will
receive a prenatal supplement with 200 mg DHA and
required not to use another prenatal with DHA.
Each study site location will have a separate ran-
domization code. Using a Bayesian Adaptive Design, a de-
cision will be made at each interim analysis. The
randomization structure will be updated depending upon
the birth outcomes. The primary endpoint, the percentage
of spontaneous ePTB, will drive the adaptive ran-
domization. The data will be analyzed after 150 partic-
pants are enrolled in each group and the randomization
schedule updated. The arm that looks to be the best will
get more pregnant women allocated to it in this subse-
quent randomization. A new adaptive randomization
schedule will be generated every 13 weeks using up to date
outcome data until the trial is stopped. Both the initial
and subsequent updated tables will be attached to our
eResearch tool [89]. Steps for randomization in eResearch
include:
❖ Subject demographics are entered
❖ Subject is attached to study (at this point patient
status could be screening or pre-screening)
❖ Verification of inclusion and exclusion criteria and
documentation of the informed consent are entered
into the patient randomization form triggering
automatic assignment of a patient study ID and
Table 2 Inclusion and exclusion criteria
Inclusion criteria
1. Pregnant females 18.0 years and older 12 to 20 weeks of
gestation at study entry
2. Agree to consume study capsules and a typical prenatal
supplement of 200 mg DHA
3. Available by telephone
4. English or Spanish speaking
Exclusion criteria
1. Less than 18 years of age
2. Expecting multiple infants
3. Gestational age at baseline <12 weeks or >20 weeks
4. Unable or unwilling to agree to consume capsules until delivery
5. Unwilling to discontinue use of another prenatal supplement
with DHA
6. Women with allergy to any component of DHA product
(including algae), soybean oil or corn oil
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randomization to the next particular arm from the
allocation table
We will test if the randomization is effective by ensur-
ing the groups are similar at baseline (pre-randomization
variables) for all such predictor variable and will be
presented in a table per CONSORT guidelines [90].
Placebo and DHA supplementation
A marine algae oil source of DHA (DSM, Columbia,
MD) will be provided in capsules. Specific capsules to be
used are equivalent to Spring Valley Algal-900 DHA
Dietary Supplement Softgels, 450/mg per capsule. The
algal oil capsules in this study provides 800 mg DHA in
two (2) 1-g capsules and the higher DHA group of sub-
jects will be asked to consume two capsules per day.
The placebo control group will receive two (2) 1-g
capsules containing half soybean oil and half corn oil.
The soybean and corn oil combination does not contain
DHA. Two capsules provide 80 mg of α-linolenic
acid, a precursor of DHA. On average, US adults con-
sume ~1000 mg/d of α-linolenic acid but can make only
about ~40 mg DHA/day. Both capsules will be prepared
and provided with orange flavor to mask the taste if there
is eructation. The placebo and masked DHA capsules will
be provided in bottles of 100 capsules (a supply for
50 days). DSM (Columbia, MD) will donate the capsules
and the 200 mg DHA capsules to both groups for daily
use. The latter are available commercially as a prenatal
supplement marketed under several product names. The
200 mg capsules will be provided in bottles of 135 cap-
sules (135-day supply) and will be marked with an expir-
ation date. Other fatty acids found in the capsules do not
contribute significantly to the amounts in the diets of US
women. DHA is the only fatty acid expected to change in
the RBC-phospholipids (PL) of the supplemented group.
Patient compliance will be monitored and encouraged; in
our previous trial, on average 74% of capsules were
consumed.
Capsule records and accountability
The Investigational Pharmacy at The University of
Cincinnati will mail capsules to each enrolled participant
on a regular schedule until delivery when the bottles and
any remaining capsules are to be returned by mail to the
Investigational Pharmacy in a self-addressed envelope
provided with capsule delivery. The remaining capsules
will be counted, the number recorded and the capsules
destroyed. Records of capsules mailed to and received
back from subjects will be entered into the study data-
base with a flag to investigators at the subject’s study
site. Investigators at each site will review the database
and contact participants who do not return their capsule
bottle. Study personnel will contact the participant by
telephone early within the first month and monthly
thereafter to determine if there are any problems and
encourage compliance. The study investigator, study site
staff and participants will not know which study arm
capsules are being consumed by any patient. The
Investigational Pharmacy at the University of Cincinnati
will receive all bottles of capsules directly from DSM
and will maintain packing receipts for study products.
Blood collection
Maternal blood samples will be collected at enrollment
and the morning following delivery by venipuncture. At
enrollment and delivery, two 4-ml potassium–EDTA
tubes will be obtained (BD Vacutainer, Franklin Lakes,
NJ), placed on ice immediately and processed within
24 hours. Plasma, buffy coat and anticoagulated RBCs will
be separated by centrifugation (3000×g, 10 min, 4 °C). At
the University of Kansas Medical Center, an additional
one 7-ml potassium-EDTA tube and one 5-ml serum tube
will be collected at enrollment and delivery for the cell
free plasma RNA analysis. Two (2) 4-ml potassium-EDTA
tube of umbilical cord blood will be obtained at delivery
and processed similar to maternal samples. All samples will
be stored snap frozen in nitrogen and stored at −80 °C for
the planned or future studies.
Fatty acid analysis
Fatty acid content in red blood cells (RBC) will be ana-
lyzed by gas chromatography. Briefly, an aliquot of
packed RBCs is extracted with organic solvents and the
dried under a nitrogen stream before transmethyation
with boron trifluoride-methanol [5]. The fatty acid
methyl esters are extracted into organic solvent, dried
under a nitrogen stream and reconstituted in dicho-
loromethane for analysis on a gas chromatograph with
flame-ionization detection equipped with an autosam-
pler using a fused silica capillary column (SP2560,
100 m × 0.25 mm id × 0.25um film thickness). Helium is
used as the carrier gas. Fatty acid analyses will be
completed at the University of Kansas Medical Center.
RBC-DHA and other fatty acids are reported as weight
percent of total fatty acids. RBC-DHA can also be used
to evaluate compliance.
sRAGE analysis
sRAGE will be determined at Nationwide Children’s
Hospital in Columbus, OH on batched samples using
ELISA-based format (MesoScale Discovery, Rockville
MD) according to the protocols of the manufacturer.
Cell free plasma RNAs
One 7-mL maternal blood sample in potassium-EDTA
tube (lavender top) and one 5-ml maternal blood sample
in serum tube (red top) will be collected from the
Carlson et al. BMC Pregnancy and Childbirth  (2017) 17:62 Page 8 of 16
subject at enrollment and delivery at KUMC to first de-
termine their a priori risk of experiencing spontaneous
preterm birth by measuring a panel of cell free RNAs,
and secondly to determine the impact of DHA of the
cell free plasma transcriptome. The four markers used in
this panel appear in in vitro studies to alter myometrial
quiescence. In validation studies of maternal samples
from pregnant women at gestational ages similar to the
current study, the spontaneous preterm labor panel has
a sensitivity of 100%, specificity of 95%, positive and
negative predictive values of 95 and 100% respectively
for spontaneous PTB less than 32 weeks of gestation
(unpublished, CP Weiner). Should the administration of
DHA alter the predicted spontaneous PTB rate in partic-
ipants with an abnormal panel, it would provide insight
as to the mechanisms by which DHA might work.
Dietary and nutrient intake
The National Cancer Institute Diet History Questionnaire
(DHQ-II) is the current version of a food frequency and
portion questionnaire. The database associated with the
DHQ-II is based on the National Health and Nutrition
Examination Surveys (NHANES) data collection from
2001 to 2006. Participants will complete the DHQ-II at
enrollment using electronic/tablet entry. Paper copies will
be available for Spanish speaking participants and English
speaking participants that reject electronic entry. The
study teams at each site will provide instruction as to how
to complete the questionnaire and review DHQ-II results
for completeness. Additional study staff may follow up with
the study participant by telephone after enrollment if there
are concerns regarding missing data, inconsistences, etc.
The project is registered at the NCI website and all
electronic data will be stored securely under the PI user
name and password until study end. Data will be
analyzed using the Diet-Calc software. The DHQ-II
provides data for 176 nutrients, dietary constituents and
food groups.
In addition to the DHQ-II, the DHA Food Frequency
Questionnaire will be administered. This questionnaire
includes targeted questions to assess the intake of
omega-3 fatty acids accurately [91]. Results of the ques-
tionnaire will be entered into the CRIS database.
Urine collection
One non-sterile urine sample (minimum collection of
8 mL) in a 4 oz. specimen collection container will be
obtained between 12 and 20 weeks of gestation ideally at
the time of enrollment and again during the 3rd trimes-
ter. The sample will be divided into four 2.0 mL cryo-
vials using a disposable transfer pipette. Cryovials will be
labeled and frozen at −80 °C until analysis. The levels of
endocrine disrupting chemicals (EDC) will be quantified
and any differences in maternal urine levels between
groups determined.
Data collection and integrity
Phase III Clinical Trials have a formal system for data
collection and scrutiny in accordance with Good Clinical
Practices (GCP) and conform with the regulatory
requirement(s) [92]. Data collection and entry for all
aspects of the study will be performed by persons at
each site. Study staff will adhere to trial-specific Stand
Operating Procedures (SOPs) approved by trial PIs.
Clinical teams at each site will maintain essential source
documents including clinical and hospital reports.
The data generated by this project will be entered at
the individual site into a CRF Part 11 compliant, secure
data system developed and managed by Dr. Gajewski’s
team in Biostatistics. The data will be fully accessible to
the other PIs at all times. An electronic case report form
that includes historical information obtained from sub-
jects not in the hospital or from their clinical record
(e.g., detailed smoking history, alcohol use – number
and type of alcoholic beverages before and during preg-
nancy using the Nutrition Educators of Health Profes-
sionals tool and DHQ-II obtained at study entry) http://
www.ich.org/fileadmin/Public_Web_Site/ICH_Products/
Guidelines/Efficacy/E6/E6_R1_Guideline.pdf will be main-
tained as the primary source document for this informa-
tion. Whenever possible, site staff will use a two-pass
approach to confirm accuracy of social/historical informa-
tion not in the hospital or clinical record (i.e., staff will re-
view data entry with subjects in person or by phone
interview). One hundred percent of data for the primary
outcome and safety (mother and newborn) and a portion
of other data collected will be double-checked by the clin-
ical teams after the data are entered into the eResearch by
reviewing source documentation. The proportion of sec-
ondary outcome data will be determined by the PIs based
on the actual incidence of errors observed in data entry.
These master files will be established for each subject and
maintained for the duration of the trial and retained ac-
cording to the appropriate regulations.
Accuracy, completeness, legibility of work documents
and timeliness of the data reported in the patient’s elec-
tronic case report form will be assured by the PI. Source
documentation supporting the case report form data will
document the dates and details of study procedures, ad-
verse events and patient status. Any discrepancies will
be explained by a note to the individual file and changes
or corrections to the electronic case report form dated,
initialed and explained (if necessary). Original data will
not be obscured.
The trial analyst will ensure data validity and accuracy
by performing edit, logic and range checks on the study
database and sending queries for resolution to the clinical
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team. Once all database queries have been resolved by the
clinical teams, the trial analyst will create the data sets for
analyses (interim and final). In collaboration with Director
of Research Information Technology, the analyst will
finalize the study binder, which will contain copies of the
annotated project case report forms, the final data diction-
ary, and copies of the electronic data files.
Primary Efficacy Outcomes
❖ Early preterm delivery (ePTB, <34 weeks gestation)
based on ACOG guidelines
Secondary Efficacy Outcomes
❖ VLBW (<1500 g) and low birth weight (<2500 g) as
recorded in hospital record
❖ Participant DHA status (RBC-PL-DHA) at enrollment
and birth; fetal DHA status at birth from cord blood
❖ Gestational age (days) at delivery based on EDD in
clinic record recorded following ultrasound on or
before ~14 weeks gestation
❖ Birth weight (g), length (cm) and head
circumference (cm) at delivery as recorded in
hospital record
❖ Preterm birth (<37 weeks) based on ACOG
guidelines
❖ Extreme preterm birth (<33 weeks)
❖ Pregnancy outcomes: gestational diabetes,
pre-eclampsia, C-section, spontaneous or induced
labor, occurrence and reason for non-routine
hospitalization
Attrition
If a patient withdraws from the study prematurely, the
assessments described at delivery that apply will be ob-
tained if available and the participant has not requested
her data not be obtained. This, and the requirement to
obtain medical records for adverse events during preg-
nancy and following birth of the infant, will be explicit
in the consent form. If the participant is withdrawn due
to an adverse event(s), the patient will be monitored
until the adverse event has resolved or until the event is
determined to be due to a stable or chronic condition.
The reason for patient discontinuation will be docu-
mented. If a patient withdraws from the study, the pa-
tient’s study number will not be reassigned.
Study termination
The study will be stopped when there is a Pr > 0.995 that
the groups are different or terminate when 1355 women
have been randomized (nmax =1200 completers after
expected dropout). The data safety monitoring board
(DSMB) may terminate the study if in the opinion of the
safety monitor there is a determination of unexpected,
significant, or unacceptable risk to the patient, however,
this is not anticipated given that safety concerns have
not arisen in other clinical trials in pregnant women that
provided large amounts of DHA. Any action taken to
suspend or terminate the project by the DSMB will be
reported to the central Institutional Review Board and




We chose this design with efficiency in mind. There is
broad acceptance that Bayesian Adaptive Designs save
time and money and lead to more ethical studies [93].
The time is right for the use of Bayesian Adaptive
Designs in comparative effectiveness clinical trials. Both
the Patient Centered Outcomes Research Institute
(PCORI), a leader in comparative effectiveness research,
and the FDA have adopted policies/guidelines en-
couraging their use [94]. Using adaptive randomization
(being able to change how we assign patients to the
drugs during the study based on information gained dur-
ing the study) allows for substantially smaller sample
sizes and provides better conclusions about what group
is the most effective, because it allows changes to our
approach or to stop the study early if strong results are
found before the scheduled end of the study [93]. We
conducted extensive trial simulations comparing differ-
ent designs measuring the resources (time and number
of patients required) and the ability to draw important
conclusions about relative efficacy of the two groups and
selected the proposed design as the most effective and
efficient. The following sections focus on different issues
and detail how we determined power, sample size, and
duration of this trial.
Summary of the Bayesian adaptive design
We will begin interim analysis once 150 subjects have
been enrolled in each group. Thereafter, interim analyses
will occur every 13 weeks with data used on all births
(intent-to-treat). There are many parameters that go into
a Bayesian Adaptive Design but highlights include after
800 subjects have been enrolled, at each interim the stop
for success is if probability (group j is best) > 0.995 for
either group and the updated allocation probabilities are
based on information weighing.
Statistical model
The statistical model will evaluate final determination of
which group is “best.” This is referred to as the group
having the lowest rate of ePTB. For this study the num-
ber of PTBs is modeled with a binomial distribution. For
the jth group the number of ePTBs, Yj, is modeled
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conditional on the number of births, nj, as a binomial
distribution Yj ~ Binom(nj,θj). θj is the rate of early pre-
term births (ePTB) of which we provide “weakly inform-
ative” priors, logit(θj) ~ N(−3.5,1.5
2). This prior not only
provides a design Type I error rate of 5% (see below), it is
also very diffuse since the point estimate of θj is 2.9%
ePTB and 95% interval 0.16–36%. This is very, very spread
out. Using the data and the prior probabilities, we then use
Markov Chain Monte Carlo computations to obtain the
Bayesian posterior distributions of θj respectively for each
group as well as calculating probability (group j is best).
Response adaptive randomization
After 150 subjects are enrolled in each group the next
round of subjects is randomized using a formula that takes
advantage of the information gained from our analyses up
to that point. Next subjects are randomly allocated to be
enrolled in the jth group proportional to Vj = [prob(group j
is best)xVar(θj)/(nj + 1)]
1/4. This formula assigns more pa-
tients to the most promising group. The study remains
blinded throughout. In response to reviewer concern that
adjustment after 150 enrollments in each group would be
too soon, PIs explored an alternative adaptive design be-
ginning after 300 enrollments in each group. The sample
size changed from 938 with 60% in the winning group to
940 with 56% in the winning groups. The average recruit-
ment length changed from 184 to 183 weeks. We chose to
stay with adjustment after 150 enrollments in each group
because it resulted in more subjects on the better dose
than the later adjustment.
Power, sample size, trial duration, and allocation
For the purposes of this investigation we looked at
several virtual (or “pretend”) responses to determine the
power, sample size, time (duration), and subject alloca-
tion needed for our study. We created several scenarios
for ePTB rates. We performed five sets of trial simula-
tions based on the various combinations of response.
Each set involved 100 trial simulations. We highlight
two scenarios here. The first uses a slightly more conser-
vative result than the KUDOS trial to predict what we
believe is the most likely response (scenario #1 in
Tables 3 and 4). If there is a best group in terms of ePTB
rate, we estimated (identified) that 82% of the simulated
trials had early success and 8% had late success. This
trial scenario had 90% power and the sample size of this
trial scenario was on average 938 (60% of these in the
winning group). The average length of this trial scenario
was 184 weeks. While a conventional equal random-
ization trial would have 90% power, it would be larger
(1200 subjects), slower (230 weeks), and have a lower
rate of subjects on the winning group (50%). The second
is the scenario that serves as our null hypothesis
(scenario #5). In this scenario there is no difference in
ePTB between the groups. Therefore, the extent to
which this scenario is “successful” actually reflects our
Type I error rate. For this scenario, we estimated
(identified) that 5% of the simulated trials had early suc-
cess, 0% late success. Thus, this trial scenario produced
an appropriate expected Type I error (α = 5%). The sam-
ple size of this scenario on average was 1188 subjects
(equally allocated across groups). The average length of
the trials under this scenario was 231 weeks.
Primary and secondary pregnancy efficacy analysis
(specific Aim 1)
The pregnancy analysis has two overall phases. The first
phase of analysis (primary) investigates, using Bayesian
posterior probability (group j is best, whether there is a
simple difference between groups (no adjustment of pre-
dictor variables). A similar continuous Bayesian model
will test sRAGE differences between groups. The second
phase of analysis (secondary) uses Bayesian multiple
logistic and continuous regression for detailed investiga-
tion as to why there are differences between groups.
All analyses will be conducted under intent-to-treat
principles. Subjects will remain in the group for which
they are randomized regardless of compliance. The
consent form will state that medical records may be
obtained from the clinic and hospital (for mother and
baby) unless a specific request in writing disallowing us
to obtain records is received. Nevertheless, we do antici-
pate some missing data. To handle missing data, logistic
regression will evaluate missing data patterns as a
Table 4 Simulated trial operating characteristics
Scenario %. %. Power Mean Mean trial
Finish Finish Subjects % Group 1 % Group 2 (Weeks)
Early Late
#1. very likely (4 vs 1%)a 82% 8% 90% 938 40% 60% 184
#2. likely (3 vs 0.5%) 84% 7% 91% 934 41% 59% 184
#3. unlikely (3 vs 1%) 52% 11% 63% 1046 44% 56% 204
#4. very unlikely (3 vs 2%) 23% 4% 27% 1142 46% 54% 221
#5. no difference (3 vs 3%) 5% 0% 5% 1188 51% 49% 231
aBased on our planned enrollment and US 2012 ePTB rates of black and white pregnancies, we anticipate 4.1% ePTB in the control group
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function of subject demographics. The two categories
will be “drop-out” and “did not drop out.” This analysis
will help us understand the missing data pattern (miss-
ing at random, missing completely at random).
Pregnancy efficacy analysis according to intent-to-treat
principles
In the first phase of analysis, we test the differences
between groups for the primary efficacy outcome (ePTB)
and its subgoup (sPTB). The approach is repeated for
secondary outcomes using Bayesian logistic and con-
tinuous regression (VLBW (<1.5 kg), maternal RBC PL
DHA) with no covariates.
Pregnancy efficacy analysis controlled for potential
predictor variables
The goal here is to find out how well DHA supplemen-
tation predicts our primary and secondary efficacy out-
comes after controlling for potential predictor variables.
In the second phase of analysis, using multiple linear re-
gression (logistic and continuous), we explore the rela-
tionships among predictor variables for regression and
all primary and secondary pregnancy outcomes. The
predictor variables represent five general classes: overall
DHA intake, diet (intake of nutrients and foods analyzed
by principal component analysis), environment, subject
demographics, and maternal medical history. For ex-
ploratory purposes, the most important relationship is
between the DHA dose and pregnancy outcomes. Notice
that instead of a grouping variable representing groups,
we utilize DHA in the form of several predictor vari-
ables, depending on their source.
❖ A final exploratory analysis investigates the impact
of capsule intake on outcome as mediated by
maternal RBC-PL DHA. Using a reasonable set of
predictor variables from the regressions above, we
will run two sets of regressions for each outcome
variable. This will allow maternal RBC DHA to be a
mediator. First we regress the RBC-PL DHA level
on all appropriate predictor variables (as above).
Then we will run a regression of outcome variables
on RBC-PL DHA level and all other appropriate
predictor variables (as above but with RBC DHA
added). In this way, we are running a path analytic
model where we can obtain direct effects of
variables and indirect effects of variables through
mediator plasma level.
❖We will investigate local model adequacy in all
regression analyses by exploring standardized
residuals and leverage points via Cook’s distance.
Possible co-linearity among predictor variables will
be examined with Pearson’s correlation coefficient
and variance inflation factors (VIF). Scatter plots
and histograms will also be used to investigate the
adequacy of the model assumptions.
❖ Of substantive interest in the regression analysis is
that race is one of the predictor variables. Since we
anticipate 22.5% of the subjects to be Black American
of African descent, we can test whether efficacy of
pregnancy outcomes are different for Black American
women of African descent relative to other races.
❖ For regression analysis purposes, the pregnancy
outcomes are separated into two classes of variables,
either continuous or dichotomous. For the continuous
variables, Bayesian regression based on the normal
distribution will be utilized. For the dichotomous
variables, logistic regression will be utilized.
❖ For all outcomes, we set the DHA dose as a
predictor variable and then fit all possible subsets of
the other predictor variables to explore, for the
particular pregnancy outcome, which model is the
best. We will utilize a global fit index called
Deviance Information Criteria (DIC) to determine
which variables to keep in the final model. The DIC
is very general and can be used for normal and
logistic regression analyses.
Potential predictor variables for regression analysis
Class 1: Overall DHA intake
❖ DHA dose (capsules taken multiplied by the DHA
in the type of capsule consumed)
❖ maternal RBC-PL DHA level at enrollment and
delivery (g DHA per 100 g total fatty acids) by
chromatographic analysis
❖ umbilical cord RBC DHA by chromatographic
analysis
❖ estimated DHA intake at enrollment from DHQ-II
and frequency/amount of consumption of food and
supplement sources containing DHA
Class 2: Diet
❖ estimated DHA intake at enrollment from DHQ-II
and frequency/amount of consumption of food and
supplement sources containing DHA
❖ intake of other nutrients or foods, e.g.,
macronutrient quantity or quality, micronutrient
quantity at enrollment
Class 3: Exposure to environment
❖ tobacco exposure prior to and during pregnancy by
subject report
❖ alcohol intake prior to and during pregnancy by
subject report defined as standard drinks/day
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(Nutrition Educators of Health Professionals
Teaching Tool)
❖ measurement of endocrine disrupting chemicals (EDCs)
in urine at 12–20 weeks and 33–36 weeks of gestation
❖ potential exposure to EDCs in environmental by
questionnaire at 12–20 weeks and 22–26 weeks of
gestation
Class 4: Subject demographics
❖ marital/relationship status, by subject report
❖ household income by subject report
❖ insurance type (private, public, uninsured) by review
of clinic/hospital record
❖ maternal and paternal education by subject report
❖ maternal age at enrollment (years) from DOB listed
in clinic/hospital record
❖ maternal and paternal race/ethnicity from clinic
record or subject report
❖ fetal sex
Class 5: Maternal medical history
❖ BMI calculated from the measured prenatal clinic
weight record and measured height during the first
prenatal visit, or if missing, the self-reported
pre-pregnancy weight
❖ gestational weight gain (last clinic visit in pounds
minus 1st measured weight or pre-pregnancy weight)
❖ gestational age at enrollment (days) calculated from
EDD (based on ACOG guidelines)
❖ reproductive history
❖ characteristics of previous pregnancies (early
preterm birth, pre-eclampsia, gestational diabetes)
blood pressure throughout pregnancy
❖ iron status/hemoglobin at enrollment and mid-
pregnancy
❖ cervical length between 18 and 22 weeks of
gestation if reported
❖ estimated blood loss at delivery by estimate of the
deliverer
❖ infant APGAR scores
❖ meconium in amniotic fluid
❖ evidence of illicit drug use from clinic/hospital
record
Safety monitoring
A DSMB composed of two neonatologists, one pediatric
pharmacologist and one pediatric epidemiologist will
meet yearly and generate a report to the PIs and IRB.
The medical monitor will chair DSMB discussions. They
will receive all reportable adverse events (i.e., events that
are unexpected and related or probably related) within
five working days after the investigators learn of the
event. They will also be provided a complete list of all
AEs by the trial analyst prior to each DSMB meeting.
The medical monitor may request the actual product
assigned to an individual if needed. After all data for the
study have been monitored, entered, cleaned and locked,
a safety report will be generated by the study analyst
with input from the medical monitor to generate the
safety report for publication.
Responsibilities and management plan
The submission of this proposal with Drs. Susan E.
Carlson, Christina Valentine and Byron Gajewski as prin-
cipal investigators represents a unique collaboration of
three scientists with a strong interest in the nutrient
DHA but representing different key disciplines and ex-
periences to work together to conduct a clinical trial that
requires several clinical sites to meet the planned re-
cruitment goal needed to test the hypothesis that DHA
can reduce early preterm birth (ePTB). Dr. Carlson and
Dr. Byron Gajewski have collaborated on an NIH funded
trial (R01 DHA and Pregnancy Outcome) since 2005.
The two are also working in collaboration with the PIs
from the DOMInO trial in Australia to determine
women who most benefited from DHA supplementation
to reduced ePTB in that trial; and have generated pre-
liminary data shared in this proposal. Dr. Valentine is a
neonatologist who initially trained as a dietitian who has
conducted two trials in maternal dietary DHA and hu-
man milk composition that have an FDA IND. She has
worked in the field of neonatology as a physician since
2002 and has a goal of improving perinatal nutrition.
She is a co-investigator on an NIH funded R01 trial from
the Office of Dietary Supplementation to examine the
inflammatory homeostasis of preterm infants after
maternal DHA supplementation. She was previously at
Nationwide Children’s Hospital and The Ohio State for
9 years and maintains a strong collaboration with her
previous mentor Dr. Lynette Rogers who is site PI at
Nationwide Children’s Hospital.
For the current proposal, Dr. Gajewski’s role as a PI is to
design and govern the Bayesian Adaptive Design. He has
expertise in the design and implementation of Bayesian
adaptive designs. He has published new Bayesian clinical
trials methodology in a top tier biostatistics journal
(Statistics in Medicine), of which one was quoted in
NHLBI’s RFA-HL-08-013. He has also published two pa-
pers showcasing novel Bayesian predictors of clinical trials
accrual with co-PI Carlson. He was also successful in
gaining PCORI (CER-1306-02496) funding using a novel
Bayesian adaptive design. His experienced team in
Biostatistics will also set up and manage a common secure
data entry system for the three study sites and be respon-
sible for generating the initial and subsequent (adaptive)
randomizations that will be used by the Investigational
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Pharmacy at the University of Cincinnati to allocate the
supplement to subjects at all three sites. He will be
responsible for the randomization, setting up a common
secure data entry system for the three proposed study sites
(University of Cincinnati, Ohio State University, and the
University of Kansas Medical Center) and for managing
the adaptive design. With his Co-PIs, Carlson and
Valentine, he will be primarily responsible for the statis-
tical analysis for the study.
Dr. Carlson will interface with a study coordinator at
KUMC and Dr/Valentine with the study coordinators re-
sponsible for managing both the Cincinnati and Columbus,
OH sites. Monthly teleconference will be used to discuss
any issues of recruitment and retention at any site. The
teleconference will include the PIs (Valentine, Gajewski,
Carlson) and the key personnel at UC, OSU and
Nationwide (DeFranco, Buhimschi, Rogers) the trial ad-
ministrator (Kerling) and study coordinators at each
site (Thodosoff, Smith, Caldwell). Because we have
already conducted a nearly identical intervention at
Kansas City, we do not anticipate a lot of new issues.
We have developed a system and understand the work-
load engendered by the proposed study and so could be
helpful in advising Dr. Valentine what will be needed
for the two Ohio sites. The teleconferences will be used
to review and provide updates on enrollment, testing,
and data collection over the previous month provided
by the leaders of each of the teams. Carlson, Valentine
and Gajewski will communicate at least weekly through
email or telephone conversation. Kansas City and
Cincinnati are only ~90 min apart by air. The PIs will
meet face-to-face 6 months into the recruitment and
yearly or as needed after that. The PIs have already
developed open channels of dialogue that are exercised
frequently in the writing of this proposal. Bridge lines,
video conferencing, e-mail and shared digital access
systems are available as needed.
Data access, dissemination, and authorship
Typically, with longitudinal projects like this one, deci-
sions as to how and when to publish empirical reports is a
difficult one. To resolve this issue, the PIs will map out a
preliminary dissemination plan that is principled yet flex-
ible enough to allow for the clearest manner of presenting
the results, and to determine the extent of authorship.
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